The Company's 2021 consolidated financial statements have been reported to the Board
· Issued by Synmosa Biopharma Corp
Close
Today's Information
Provided by: SYNMOSA BIOPHARMA CORPORATION
SEQ_NO
2
Date of announcement
2022/03/29
Time of announcement
15:27:36
Subject
The Company's 2021 consolidated
financial statements have been reported to the Board
Date of events
2022/03/29
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/29
2.Date of the audit committee approved:2022/03/29
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):3,234,960
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):1,285,368
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):184,530
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):153,886
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):116,075
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):303,860
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.02
11.Total assets end of the period (thousand NTD):10,316,783
12.Total liabilities end of the period
(thousand NTD):4,221,421
13.Equity attributable to owners of parent end of the
period (thousand NTD):4,705,519
14.Any other matters that need to be specified:none
